Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.

doi:10.1038/clpt.1991.22

Back to search

Article

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.

Clinical pharmacology and therapeutics - 1 Mar 1991

von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F

Abstract excerpt

The pharmacokinetics of thioridazine and its metabolites were studied in 19 healthy male subjects: 6 slow and 13 rapid hydroxylators of debrisoquin. The subjects received a single 25 mg oral dose of thioridazine, and blood samples were collected during 48 hours. Concentrations of thioridazine and...

Topics

Adult
Antidepressive Agents
Debrisoquin
Humans
Hydroxylation
Male
Mesoridazine
Phenothiazines
Phenotype
Thioridazine

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.